The purpose of this Core C (Virus Core) is to provide a time- and cost-efficient, quality-controlled mechanism by which all 7 research groups associated with this Program Project will have ready access to high-titer stocks of the wild-type (WT) and mutant viruses they will need for their proposed studies.
The Specific Aims are: (1) to produce high-titer stocks of WT and mutant Epstein-Barr viruses (EBVs); (2) to produce high-titer stocks of WT and mutant human cytomegaloviruses (HCMVs); (3) to produce stocks of WT and mutant hepatitis B viruses (HBVs); and (4) to produce stocks of infectious mouse papillomavirus (MusPV) and human papillomavirus (HPV) pseudoviruses. Mutant EBVs (for Projects 3, 4, and 5) will be generated in E. co//starting with appropriate BACs using the markeriess two-step red-mediated recombination protocol of Tischer ef al. (2006). In addition to standard methods, the correctness of EBV mutant variants will be confirmed by the use of high throughput DNA sequencing to circumvent, hopefully, the need to generate and characterize wild-type reverts of them. High-titer virus stocks of WT and mutant variants of EBV will be generated using a protocol developed by Dr. Sugden, titered, and stored for use by all three EBV groups. WT and mutant variants of HCMV (for Project 3) will be generated starting with appropriate BACs also using the Tischer et al. protocols; the WT and mutant HCMVs will be plaque-purified, grown into high-titer virus stocks, and the titers ofthe stocks determined in primary human fibroblasts by standard methods. WT, infectious HBV virions will be produced (for Project 2) from HepAD38 cells, a HepG2 derivative that is stably transfected with a tetracycline-repressed (tet-off), inducible HBV expression system. HBV mutants will be constructed by recombinant DNA approaches in the on-P vectors already developed by the Loeb laboratory. Papillomavirus virions and pseudovirions will be generated (for Project 1) by co-transfection of 293T cells with (i) the desired capsid protein-expression plasmids, and (ii) the desired viral or luciferase/GFP-encoding DNAs targeted for encapsidation using protocols previously published by the Lambert/Ahlquist laboratories. In addition to increased cost efficiency and quality control, the existence of this Core will also result in the use of common virus stocks that will make the interpretation of complementary data generated among the various research groups more reliably merged toward achieving shared aims within the projects. All 7 research groups associated with the 5 projects will be served by this Core facility as needed. It will be the first and only one of its type on the UW-Madison campus.

Public Health Relevance

The purpose of this Virus Core is to provide a time-efficient, cost-efficient, quality-controlled mechanism by which all seven research groups associated with this Program Project will have ready access to high-titer stocks of the wild-type and mutant viruses they will need for their proposed studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
United States
Zip Code
Djavadian, Reza; Hayes, Mitchell; Johannsen, Eric (2018) CAGE-seq analysis of Epstein-Barr virus lytic gene transcription: 3 kinetic classes from 2 mechanisms. PLoS Pathog 14:e1007114
Chakravorty, Adityarup; Sugden, Bill (2018) Long-distance communication: Looping of human papillomavirus genomes regulates expression of viral oncogenes. PLoS Biol 16:e3000062
Chiu, Ya-Fang; Sugden, Bill (2018) Plasmid Partitioning by Human Tumor Viruses. J Virol 92:
Shin, Myeong-Kyun; Payne, Susan N; Bilger, Andrea et al. (2018) Activating Mutations in Pik3caContribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes. Clin Cancer Res :
Hoebe, Eveline; Wille, Coral; Hagemeier, Stacy et al. (2018) Epstein-Barr Virus Gene BARF1 Expression is Regulated by the Epithelial Differentiation Factor ?Np63? in Undifferentiated Nasopharyngeal Carcinoma. Cancers (Basel) 10:
Nyman, Patrick E; Buehler, Darya; Lambert, Paul F (2018) Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis. Clin Cancer Res 24:6308-6318
Weng, Chao; Lee, Denis; Gelbmann, Christopher B et al. (2018) Human Cytomegalovirus Productively Replicates In Vitro in Undifferentiated Oral Epithelial Cells. J Virol 92:
Bristol, Jillian A; Djavadian, Reza; Albright, Emily R et al. (2018) A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog 14:e1007179
Romero-Masters, James C; Ohashi, Makoto; Djavadian, Reza et al. (2018) An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog 14:e1007221
UmaƱa, Angie C; Iwahori, Satoko; Kalejta, Robert F (2018) Direct Substrate Identification with an Analog Sensitive (AS) Viral Cyclin-Dependent Kinase (v-Cdk). ACS Chem Biol 13:189-199

Showing the most recent 10 out of 434 publications